[Influence of cytostatic combination therapy with vincristine sulphate and iphosphamide on blood coagulation].
Disorders of blood coagulation were investigated before and during a cytostatic combination therapy with vincristine sulphate and iphosphamide (Asta Z 4942) in 12 patients with malignant tumours or haemoblastoses.  Thromboplastin time, partial thromboplastin time, thrombin time, heat-dependent fibrin, clot retraction, and clotting factors II, V, VIII, IX, X, and the platelet count were determined. A change in the plasmatic coagulation system attributable to the combination therapy could not be demonstrated in any patient.  The influence of the cytostatic combination on the platelet-dependent haemostasis was small; a decrease in platelet count could be observed in only one patient, in whom an additional causative damage to thrombopoiesis due to the underlying disease could be assumed.  Regardless of the cytostatic therapy there were indications of a hypercoagulability in 10 patients.  This explains the increased susceptibility of such patients for thromboses or consumption coagulopathy.
D000328:Adult; D000368:Aged; D001772:Blood Cell Count; D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000032:analysis; D001780:Blood Coagulation Tests; D001792:Blood Platelets; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004359:Drug Therapy, Combination; D005260:Female; D005337:Fibrin / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D013916:Thrombelastography; D014750:Vincristine / Q000008:administration & dosage / Q000494:pharmacology*
D001779:Blood Coagulation Factors; D014750:Vincristine; D003520:Cyclophosphamide; D005337:Fibrin
Der Einfluss einer zytostatischen Kombinationsbehandlung mit Vincristinsulfat und Ifosfamid auf das Blutgerinnungssystem